Kumar Neil 的 Form 4 申報
BridgeBio Pharma, Inc.（BBIO），2026/8/20 申報
- 申報編號
- 0001470831-26-000848
- 申報時間
- 2026/8/20 16:31 ET
- 交易日
- 2026/8/18-8/19
- 申報延遲
- 2 天
- 10b5-1 計畫
- 有勾選
這份申報列了 7 筆非衍生性交易。公開市場賣出合計 $372.7 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Kumar NeilCIK 0001742485 | 董事、高階主管（執行長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/8/18 | Common Stock | S賣出處分 | −1,900 | $81.15F2 | −$154,183.86 | 276,407 | 直接 | |
| 2026/8/18 | Common Stock | S賣出處分 | −17,279 | $82.21F3 | −$1,420,513.5 | 259,128 | 直接 | |
| 2026/8/18 | Common Stock | S賣出處分 | −14,602 | $82.99F4 | −$1,211,852.1 | 244,526 | 直接 | |
| 2026/8/18 | Common Stock | S賣出處分 | −1,199 | $83.77F5 | −$100,444.07 | 243,327 | 直接 | |
| 2026/8/19 | Common Stock | S賣出處分 | −8,100 | $83.86F6 | −$679,256.28 | 507,586 | 間接 | |
| 2026/8/19 | Common Stock | S賣出處分 | −1,800 | $84.69F8 | −$152,436.06 | 505,786 | 間接 | |
| 2026/8/19 | Common Stock | S賣出處分 | −100 | $85.65 | −$8,565 | 505,686 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F8
Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。